Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Good reasons to develop the out-of-hospital follow-up after breast cancer].
Dubot C, Donnadieu A, Houzard S, Fridmann S, Dehghani C, Dagousset I, Missey-Kolb H, Hassoun D. Dubot C, et al. J Gynecol Obstet Biol Reprod (Paris). 2016 Jan;45(1):98-9. doi: 10.1016/j.jgyn.2015.09.007. Epub 2015 Dec 17. J Gynecol Obstet Biol Reprod (Paris). 2016. PMID: 26705607 French. No abstract available.
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R. Hequet D, et al. Among authors: dubot c. PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017. PLoS One. 2017. PMID: 29045452 Free PMC article.
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo ERD, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M. Scholl S, et al. Among authors: dubot c. EBioMedicine. 2019 May;43:253-260. doi: 10.1016/j.ebiom.2019.03.069. Epub 2019 Apr 2. EBioMedicine. 2019. PMID: 30952619 Free PMC article.
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek E, Saint-Martin C, Pierga JY, Brain E, Rouzier R, Savignoni A, Mouret-Fourme E, Dieras V, Piot I, Dubot C, Carton M, Lerebours F. Kaczmarek E, et al. Among authors: dubot c. Breast Cancer Res Treat. 2019 Dec;178(3):505-512. doi: 10.1007/s10549-019-05423-5. Epub 2019 Sep 5. Breast Cancer Res Treat. 2019. PMID: 31486993
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E, Espié M, Guiu S, D'Hondt V, Dieras V, Sablin MP, Brain E, Neffati S, Pierga JY, Bidard FC. Jacot W, et al. Among authors: dubot c. Breast Cancer Res. 2019 Nov 14;21(1):121. doi: 10.1186/s13058-019-1215-z. Breast Cancer Res. 2019. PMID: 31727113 Free PMC article. Clinical Trial.
65 results